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Summary Clinico-cytogenetic correlations were assessed in 88 patients with malignant ovarian tumours.
Cytogenetic analysis of the primary tumours yielded normal karyotype (N) in 33 patients and abnormal
karyotypes (A) in 55 patients. Within the A group, seven tumours had simple abnormalities (AS), i.e.,
numerical changes only or a single structural aberration, and 48 had karyotypes with complex aberrations
(AC). A correlation analysis between groups N and A revealed that cytogenetic abnormalities were more often
found among seropapillary tumours, and that cases with abnormal karyotypes on average were of higher stage
and more often had residual tumour mass after initial surgery (P<0.05 for all variables). When the three
groups N, AS, and AC were compared, they were found to be significantly different with regard not only to
the three parameters mentioned above, but now tumour grade also appeared to correlate with karyotypic
pattern (P = 0.001), with poorly differentiated tumours having the most complex karyotypes. In a correlation
analysis between karyotypic pattern and survival, group A patients had shorter survival than group N
(P = 0.049). In the corresponding analysis between groups N, AS, and AC, the differences were also significant
(P = 0.039), with shorter survival in group AC than in groups N and AS. Stage, grade, residual tumour after
primary surgery, and performance status also correlated with survival time. A multivariate analysis identified
abnormal karyotype as being independently associated with short survival in advanced clinical stages
(P = 0.030) of ovarian carcinoma. We conclude that cytogenetic analysis of tumour cells may be of clinical
value in the assessment of prognosis in patients with malignant ovarian tumours.
Despite recent improvements in the treatment of ovarian
carcinoma patients, tumour- and host-related factors still
seem to determine the outcome to a much larger degree than
does the therapy (Swenerton et al., 1985; van Houwelingen et
al., 1989). Clinical stage, the size of the postoperative residual
tumour mass, the tumour's histologic type and grade, and
the patient's age and performance status have in numerous
retrospective analyses been identified as prognostic factors,
but their interrelationship is complex and their combined
predictive power is often weak (Marsoni et al., 1990).
In addition to these partly subjective clinical and patho-
logic parameters, several other potential prognostic factors
have also been studied in ovarian carcinoma patients. These
include steroid receptor status (Slotman et al., 1990), in vitro
chemosensitivity (Volm et al., 1985), level of CA125 antigen
(Rustin et al., 1989), DNA content as measured by flow
cytometry (Friedlander et al., 1988; Iversen, 1988; Brescia et
al., 1990), clonogenic growth in vitro (Dittrich et al., 1991),
oncogene expression (Berchuck et al., 1990), and growth
factor receptor expression (Bauknecht et al., 1989; Berchuck
et al., 1991). However, the significance of these parameters as
independent prognostic factors remains unclear.
The karyotype has been demonstrated to be of prognostic
value in patients with acute myeloid leukaemia (Arthur et al.,
1989), acute lymphoblastic leukaemia (Bloomfield et al.,
1989), myelodysplastic disorders (Pierre et al., 1989), and
non-Hodgkins lymphoma (Fifth International Workshop on
Chromosomes in Leukemia-Lymphoma, 1987). Because the
cytogenetic data base is so much more limited for non-
haematologic neoplasms, only few attempts have hitherto
been made to correlate karyotypic findings with clinical para-
meters in patients with solid tumours (e.g., Rydholm et al.,
1990; Trent et al., 1990; Lundgren et al., 1991). We examined




During 28 months in 1988-1990 successful cytogenetic analy-
sis after short-term culture was performed on tumour
samples from 88 previously untreated patients with primary
malignant tumours of the ovary (Table I). All samples were
obtained at the time of initial surgery. The tumours were
classified histologically using standard WHO criteria (Serov
et al., 1973). Although mixed mesodermal tumours have been
classified by WHO as common epithelial tumours, they con-
tain both carcinomatous and sarcomatous components
(Clarke, 1990) and the four tumours of this type were group-
ed separately (Table I). The carcinomas were histologically
graded as well differentiated, moderately differentiated, and
poorly differentiated (Czernobilsky, 1987). Five borderline
carcinomas were also included in the study. Staging (FIGO,
1988) was based on the findings at surgical exploration.
The mean age of the patients at the time of surgery and
cytogenetic analysis was 62.5 years (range 24-87 years).
Sixty-five patients were in good general condition (Karnofsky
index 90-100), whereas 23 patients had poorer performance
status (Karnofsky index <80). The patients were monitored
regularly after primary surgery and clinical data were col-
lected until death or March 1, 1991. Median follow-up time
from surgery was 12.5 months for the entire group (range
2.5-26.8 months). The median follow-up time for the groups
with normal, abnormal, simple, and complex karyotypes (see
below) was 13.5, 10.0, 8.8 and 11.0 months, respectively.
Following informed consent, 73 of the 88 patients received
combination chemotherapy after surgery: cisplatin + cyclo-
phosphamid (41 patients), other cisplatin-based combinations
(15 patients), and doxorubicin + melphalan (17 patients).
After the four prescribed courses of chemotherapy, 34
patients underwent second-look laparotomy to determine the
response to therapy.
Cytogenetic methods
The culturing, harvesting, and banding techniques for
chromosome analysis have been described in detail (Pejovic
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Table I Karyotypic pattern in relation to clinico-pathologic factors of prognostic
importance in 88 patients with ovarian cancer
Karyotype
Abnormal (A)
Normal Simple Complex P-value
(N) (AS) (AC) N vs As
Prognosticfactors n = 33 n = 7 n = 48 N vs A and AC
Gradea
Well 6 5 0 0.226 0.001
Moderate 10 0 16
Poor 11 1 28
Borderline tumours 4 1 0
Histologic subtype
Seropapillary 13 4 35 0.017 0.033
Mucinous 7 2 0
Endometrioid 6 1 7
Clear cell 5 0 2
Undifferentiated 1 0 1
Mixed mesodermal 1 0 3
Stage (FIGO)
I 15 3 4 0.003 0.004
II 5 1 5
III 10 3 28
IV 3 0 11
Residual tumour after initial surgery
Present 12 2 41 0.001 0.001
Not present 21 5 7
Age
<50 3 1 6 0.122 0.264
50-69 16 4 32
> 70 14 2 10
Performance status (Karnofsky index)
90-100 27 6 32 0.188 0.237
<80 6 1 16
aBorderline tumours, mixed mesodermal tumours, and undifferentiated carcinomas are
not included.
et al., 1989). Briefly, the tumour samples were minced with
scissors, disaggregated enzymatically, and transferred onto
glass chamber slides in RPMI 1640 medium with mitogenic
additives. After 2-6 days the cultures were exposed to Colce-
mid and harvested by hypotonic treatment and repeated
fixations. G-banding was obtained with Wright's stain. All
clonal aberrations (ISCN, 1985) were identified in at least
two different in situ preparations.
For the various correlation analyses, the 88 cases were
broken down into two main categories - cases with normal
(N) vs cases with abnormal (A) karyotype. The latter group
was subdivided depending on whether the karyotype con-
tained complex (AC) or simple (AS) abnormalities; simple
abnormalities were defined as numerical changes only or a
single structural rearrangement (Pejovic et al., 1991a).
Another subdivision was based on the modal chromosome
number and stratified the abnormal clones into four groups:
hypodiploid (35-45 chromosomes), hyperdiploid (47-57
chromosomes), near-triploid (58-80 chromosomes), and
near-tetraploid (81-103 chromosomes). The two cases with a
pseudodiploid tumour karyotype were excluded from the
modal number-based analysis. The third subdivision was ac-
cording to the presence or absence of structural aberrations
involving chromosome arms 3p, 6q, lp, l9p, and 19q, all of
which have been described as nonrandomly associated with
ovarian carcinoma (Pejovic et al., 1991a).
The detailed abnormal karyotypes of all but two mixed
mesodermal and one borderline tumour have been published
(Pejovic et al., 1989; 1990a,b; 1991a,b). Thirty-three of the 88
tumours had a normal karyotype (N) and 55 had an abnor-
mal karyotype (A). Of the 55 aberrant tumours, seven had
simple karyotypic changes (AS), the remaining 48 had com-
plex karyotypes (AC) with multiple structural and numerical
abnormalities. Within the A group, 10 tumours had a hypo-
diploid chromosome number, nine were hyperdiploid, 28
were near-triploid, and six tumours had a near-tetraploid
modal chromosome number. The most frequent structural
aberrations - involving at least one-fourth of tumours with
complex karyotype changes - affected chromosome arms 3p
(17 tumours), 6q (16 tumours), llp (20 tumours), l9p (25
tumours), and 19q (12 tumours).
Statistical methods
Covariation between the karyotype and known clinico-patho-
logic prognostic factors (Table I) was estimated using the
Chi-square test. The potential prognostic importance of
karyotypic changes was assessed by comparing survival times
from surgery to death according to Kaplan and Meier (1958).
The generalised Wilcoxon's statistics was used in univariate
analyses of possible prognostic factors (Tables II and III).
Analysis of prognostic factors with simultaneous evaluation
of their relative importance was performed by the Cox (1972)
regression model (Table IV). The potential covariation of the
different variables with the achievement of complete response
as the result of the primary treatment was estimated by the
Chi-square test.
Results
The number of patients with normal (N) and abnormal (A)
karyotypes, in relation to tumour stage, histologic subtype
and grade, presence of residual tumour after initial surgery,
age, and performance status, is given in Table I. An abnor-
mal karyotype was more often found in seropapillary
tumours (P = 0.017), in more advanced (FIGO stage III-IV)
disease (P = 0.003), and A cases also more often had residual
tumour after primary surgery (P = 0.001). Splitting the group
A into AS and AC did not markedly change the results,
except that also tumour grade now emerged as a factor
showing significant (P = 0.001) covariation with the karyo-284 T. PEJOVIC et al.
Table II Survival inrelation topotentialclinico-pathologic prognostic
factors in 88 patients with ovarian cancer
No. of No. of
Prognosticfactor patients deaths P-value
Grade




Seropapillary 52 11 0.170
Mucinous 9 0
Endometrioid 14 0
Clear cell 7 1
Undifferentiated 2 0
Mixed mesodermal 4 2
Stage




Residual tumour after initial surgery
Present 55 13 0.011
Not present 33 1
Age
<50 26 1 0.186
50-69 52 6
> 70 26 7
Performance status (Karnofsky index)
90-100 65 4 0.001
-<-80 23 10
Table III Survival in relation to karyotypic pattern, modal
chromosome number, and type ofstructural chromosome aberrations
in patients with ovarian cancer
No. of No. of
Karyotypicfeature patients deaths P-value
Karyotype
Normal 33 2 0.0496
Abnormal 55 12









3p changes 17 4 0.620
no 3p changes 31 8
6q changes 16 2 0.194
no 6q changes 32 10
llp changes 20 6 0.486
no lIp changes 28 6
l9p changes 26 7 0.649
no l9p changes 22 5
19q changes 13 3 0.837
no 19q changes 35 9
typic pattern (the tumours of AC cases were often poorly
differentiated, while the N and AS tumours showed higher
degrees of differentiation).
The correlation between survival and various clinico-
pathologic potential prognostic parameters is shown in Table
II. Group differences in survival time were observed when
patients were classified according to tumour grade, stage,
presence of residual tumour mass, and performance status
(P<0.05 for all variables, Table II, Figure 1). Histologic
subtype and patient age did not correlate with survival.
The correlation between survival and karyotype is given in
Table III. The A patients had shorter survival than N
patients (P = 0.0496, Table III, Figure 2a). After dividing the
Table IV Cox regression analysis showing the most important prog-
nostic factors in 52 ovarian carcinoma cases of FIGO stages III-IV
Prognosticfactora P-value Relative riskb
Age > 60 0.003 8.485
(<60= 1)
Grade - poor 0.004 19.120
(well + moderate = l)
Karyotype - abnormal 0.030 6.865
(normal = 1)
Performance status (Karnofsky index) 0.051 3.405
K80
(90- 100= 1)
aThetablerepresentsstep 1 oftheregressionanalysis; tumurstagehas
been removed from the analysis because it did not appear as an
independent prognostic parameter (P = 0.917) in step 0. bRelative risk
ofdyingrepresentsthehazard rateassociated withagivenfactorrelative
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Figure 1 Survival in 88 ovarian cancer patients in relation to
histologic grade, FIGO stage, residual tumour after initial
surgery, and performance status.
series into the three cytogenetic groups N, AS and AC in the
correlation analysis, the difference remained statistically
significant (P = 0.039), and the AC group exibited the short-
est survival (Figure 2b).
Tumour grade, clinical stage, age, and performance status
were factors used as covariates in the Cox proportional
hazard model to evaluate if karyotypic changes could predict
outcome independently (Table IV). Because there were so few
deaths among stages I-IH, only information about the 52
patients with advanced disease (stages III-IV) was used in
the multivariate analysis. Only three patients in this group
were without residual tumour after primary surgery, and
therefore this factor was not considered in the analysis.
Finally, the three mixed mesodermal tumours of stages
III-IV were excluded from the analysis because they are
regarded to constitute an entity that is separate from the true
epithelial ovarian tumours. Most carcinomas (43 of the 52)
were of the seropapillary type. Tumour grade, age, and
karyotype provided independent prognostic information on
survival in this series. The prognosis was worse for patients
with karyotypic abnormalities (all but one belonged to the
AC group) compared with those with normal karyotypes
(P = 0.030). Similarly, poorly differentiated tumours and
older age were associated with short survival (P = 0.004 and
P = 0.003, respectively). The correlation between perfor-
mance status and survival was borderline (P = 0.051).
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Figure 2 Survival in 88 ovarian cancer patients with a, normal
(N) and abnormal (A) tumour karyotypes and b, normal karyo-
type (N), abnonnal karyotype with simple aberrations (AS), and
abnormal karyotype with complex aberrations (AC).
Clinical stage III vs IV did not show any influence on sur-
vival.
When the presence of particular structural aberrations was
correlated with tumour stage, presence of residual tumour
after initial surgery, histologic subtype and grade, patient's
age and performance status (data not shown), the occurrence
of 3p changes (in 17 tumours) showed a correlation with
poor performance status (P
= 0.027) and the I lp changes (in
20 tumours) were more frequent in cases of advanced clinical
stage (P = 0.047). No difference in survival time between
patients with any particular structural aberration and those
without was found (Table III). Other comparisons between
the groups with different structural aberrations could not be
performed because some tumours had simultaneously several
of the chromosome anomalies. There was also no difference
in survival time when groups with different modal chromo-
some numbers were compared (Table III).
The relationship between karyotype
- as well as the other
clinico-pathologic factors - and response to primary treat-
ment could be evaluated in the 34 patients (seven with early
and 27 with advanced disease stage) who underwent second-
look operations. The only variable that was significantly
associated with achievement of complete remission was histo-
logic tumour grade (P
= 0.014). All three patients with well
differentiated tumours achieved complete remission, whereas
eight of the 16 patients with moderately differentiated
tumours and only two of the 14 patients with poorly differ-
entiated tumours had microscopically documented complete
remission. One mixed mesodermal tumour was not graded.
Discussion
Some cytogenetic studies performed on unbanded (Atkin,
1971) as well as banded material (Whang-Peng et al., 1984;
Trent et al., 1985) have hinted that the degree of chromo-
some alteration in ovarian carcinomas may influence patient
survival. This report is the first to statistically examine the
potential covariation between tumour karyotype and known
important clinico-pathologic parameters, and the influence of
all these potential prognostic factors on the response to
primary treatment and the survival of the patient.
Our rationale for subdividing patients with abnormal (A)
karyotypes into two subgroups, those with simple (AS) and
those with complex (AC) changes, was our earlier observa-
tion that simple karyotypic changes are much more common
in well differentiated ovarian carcinomas than in moderately
and poorly differentiated tumours (Pejovic et al., 1990b,
1991a). Both in the N vs A analysis and in the N vs AS and
AC comparisons the karyotypic pattern showed correlation
with tumour stage, histologic type, and age of the patient.
However, only when the A group was subdivided into AS
and AC were the histologic tumour grade and karyotypic
pattern significantly correlated (Table I): well differentiated
carcinomas tended to have normal or simple karyotypes,
whereas poorly differentiated tumours tended to have com-
plex karyotypes. Also, tumours of stages III-IV more often
had complex karyotypes than tumours of early stages. Simi-
lary, patients with N or AS tumour karyotypes were more
frequently tumour-free after the initial operation than AC
patients. All these results are in agreement with the generally
accepted view of gradual accumulation of genetic alterations
during tumour progression, with more malignant tumours
having more aberrant karyotypes (Nowell, 1976). Complex
karyotypes were also more frequently found among seropa-
pillary carcinomas, whereas mucinous and clear-cell carcin-
omas tended to have normal karyotypes.
Of the subsets defined by the presence of particular struc-
tural chromosomal abnormalities, only tumours with Ilp
changes showed a correlation with advanced clinical stage
and tumours with 3p aberrations correlated with poor perfor-
mance status. These associations could well be spurious and
reflect chance significances rather than reproducible bio-
logical mechanisms. There was no association between a
l9p + chromosome, the most frequent structural aberration
in our series, and any of the prognostic parameters. The
presence of similar l9p + chromosomes has in patients with
malignant fibrous histiocytoma been associated with increas-
ed risk of relapse (Rydholm et al., 1990).
The factors generally accepted as predicting survival length
in ovarian carcinoma patients (Swenerton et al., 1985) were
shown to be of importance also in our series: grade, stage,
residual tumour, and performance status were all significantly
correlated with survival (Table II, Figure 1). No similar
correlation was found for histologic type, which is in agree-
ment with reports stressing that grading provides more prog-
nostic information than histopathologic diagnosis in ovarian
carcinoma patients (Sorbe et al., 1982; Malkasian et al.,
1984). The degree of cytogenetic complexity was strongly
correlated with outcome: not only did patients with abnor-
mal karyotypes have shorter survival than those with normal
karyotypes, but also within the A group the AC cases had
shorter survival than the AS cases (Table III, Figure 2a,b).
On the other hand, no difference in survival was apparent
between patients with normal tumour karyotypes and those
belonging to the AS subset. It is at present uncertain whether
this reflects favourable prognosis for the AS group or wheth-
er the similarity would disappear with longer observation
time and when more patients are examined. In the multi-
variate analysis (Table IV), abnormal karyotype was shown
to be an independent prognostic discriminator for patients
with advanced (stage III-IV) seropapillary ovarian carcin-
omas, though not with higher predictive power than grade
and age. The findings are in accordance with previous flow
cytometric studies showing that an aneuploid DNA content
in the tumours has an adverse effect on the survival of the
patient (Friedlander et al., 1988; Iversen, 1988; Klemi et al.,
1988; Brescia et al., 1990).
The only cytogenetic parameter that in previous studies
was suggested to be of prognostic importance in ovarian286 T. PEJOVIC et al.
carcinoma patients was the modal chromosome number:
Trent et al. (1985) found correlation between hypodiploid,
and particularly near-haploid, ovarian cancers and poor out-
come. There was no near-haploid tumour present in our
series, but in general we saw no difference in survival
between different ploidy groups.
In spite of a short follow-up time and relatively small
number of patients in our study, the tumour karyotype could
nevertheless, for the first time, be demonstrated to be an
independent prognostic parameter in ovarian cancer patients.
But even if the finding of a normal or minimally altered
karyotype indicates that an ovarian cancer patient has a
relatively favourable prognosis, it is apparent that not all
these cases follow an indolent clinical course. This may for
some tumours be explained by our failure to detect cytogen-
eticially the abnormal clones. Any tumour sample consists of
a mixture of parenchyma and stroma cells, and preferential
outgrowth of the latter leads to the impression of a normal
tumour karyotype although the parenchymal elements may
have harboured abnormalities. Improvement of the tissue
culturing techniques as well as the combined use of
cytogenetic and flow cytometric analyses may in the future
result in better identification of patients with favourable pro-
gnosis.
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study was financially supported by the Swedish Cancer Society, the
Lund University Medical Faculty, and the JAP Foundation for
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